Argenx stock advances on strong quarterly revenue

Argenx stock reflects a company that is still scaling fast: in the second quarter of 2026, total revenue reached €806.5 million, up 40% year over year, while product net sales rose to €507.1 million. The company also reported €182.5 million in net profit for the quarter, showing that growth and profitability are moving in the same direction.

Revenue up 40%

The second-quarter numbers matter because they show more than a single product story. Argenx said the quarter included €507.1 million in product net sales and €806.5 million in total revenue, which means the commercial base widened further in Q2 2026.

That 40% year-over-year increase is the key comparison. It gives the current quarter a clear reference point and helps explain why the stock can remain sensitive to every update on demand, launches, and the pace of uptake.

Profit also turned higher

Profitability adds another layer to the picture. Argenx posted €182.5 million in net profit in Q2 2026, compared with a loss in the prior-year period, indicating that the revenue scale is beginning to filter through to the bottom line.

For investors, the combination of €806.5 million in revenue and €182.5 million in net profit is more relevant than a single headline number. It suggests that the market will likely keep paying attention to margin quality, not only to topline growth.

Vyvgart remains the key product

Vyvgart remains the companys central commercial driver and the product investors watch most closely in every quarterly update. Its contribution is visible in the €507.1 million of product net sales reported in Q2 2026, which points to continued demand across the franchise.

The stock story is therefore tied to execution rather than hype. As long as Argenx keeps delivering revenue growth, sales conversion, and profit improvement in the same reporting cycle, each quarterly release can matter more than broad sector sentiment.

Price and market view

Argenx closed the latest session at EUR 563.80 on Nasdaq as of 27 July 2026, with a market capitalization of EUR 34.1 billion as of the same date. Those figures place the shares among the larger European biotech names and make the quarterly operating line even more important for valuation.

At the same time, the 40% year-over-year revenue increase and the shift to €182.5 million in quarterly net profit give the stock a fundamental anchor beyond day-to-day trading. That mix is what keeps Argenx relevant to both growth-oriented and quality-focused investors.

Vyvgart sales engine

Vyvgart is the cleanest way to read Argenx’s quarter because it links product sales directly to the company’s broader financial profile. The €507.1 million in product net sales in Q2 2026 shows that the franchise continues to carry most of the commercial weight.

Shares at EUR 563.80

Argenx stock traded at EUR 563.80 on 27 July 2026, with a market capitalization of EUR 34.1 billion on the same date. Those levels make the Q2 2026 revenue, product sales, and profit figures the main numbers to watch in the next update.